UPMC's neurosurgical team may recommend a combination of surgical and non-surgical approachesfor hemangiopericytoma treatment.
Minimally invasive surgery
Surgical removal of the tumor is the primary treatment.
Hemangiopericytomas of the skull base may be approached directly using the Endoscopic Endonasal Approach (EEA). This state-of-the-art, minimally invasive approach allows surgeons to access the tumor through the natural corridor of the nose, without making an open incision. Surgeons then remove the hemangiopericytoma through the nose and nasal cavities.
EEA offers the benefits of no incisions to heal, no disfigurement, and a faster recovery time.
If you need complementary treatments, such as radiation, those therapies can begin soon after EEA surgery.
When evaluating you for treatment, our neurosurgeons will look at your hemangiopericytoma from every direction. We will find the surgical path that is least disruptive to your brain, critical nerves, and ability to return to normal functioning.
Gamma Knife® radiosurgery
Gamma Knife radiosurgery is a painless procedure that uses hundreds of highly focused radiation beams to target tumors and lesions within the brain, with no surgical incision.
Gamma Knife treatment may be an option for people with residual tumor after surgery or for those who show delayed tumor progression despite an initial multipronged treatment. Gamma Knife is used to non-invasively boost the effectiveness of radiation delivered to the hemangiopericytoma tumor.
As the nation's leading provider of Gamma Knife procedures, UPMC has treated more than 12,000 patients with tumors, vascular malformations, pain, and other functional problems.
Our team may also perform stereotactic radiosurgery using the Cyberknife and other linear accelerator-based systems.
Radiation therapy and chemotherapy
Surgery may be followed by radiation therapy to prevent recurrence, usually localized to the postoperative site and particularly in cases where the tumor was not totally removed.
Chemotherapy is also effective for treating malignant hemangiopericytomas and is often prescribed after surgery.